John Ansley, MD
Otolaryngology · Orangeburg, SCNPI 1790733590
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,000 of the $11,977 with a category attached, or 75.1%. Alk-abello, Inc accounts for 75.1% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2020 at $5,359 and has fallen 85.8% since, to $760 in 2025. Among otolaryngology clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 78 payments — averaging $153.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alk-abello, Inc$9K
- Optinose US, Inc.$1K
- Stryker$440
- Regeneron Healthcare Solutions, Inc.$398
- Sanofi$298
- Acclarent, Inc$234
- plus $570 from 15 others
Across 131 payments — averaging $3820.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Hill Dermaceuticals, Inc.$343K
- Biohaven Pharmaceutical Holding Company Ltd.$137K
- IBSA Institut Biochimique SA$16K
- Smith+Nephew$3K
- Pfizer$1K
What the payments were for
- Consulting fees$8007%
- Speaking & faculty fees$9,00075%
- Food & beverage$2,17718%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alk-abello, Inc | 12 | $9,000 |
| Optinose US, Inc. | 10 | $1,038 |
| Stryker | 5 | $440 |
| Regeneron Healthcare Solutions, Inc. | 14 | $398 |
| Sanofi | 8 | $298 |
| Acclarent, Inc | 7 | $234 |
| AstraZeneca | 1 | $133 |
| Medical Device Business Services, Inc. | 3 | $89 |
| Integra Lifesciences Corporation | 2 | $77 |
| Smith+Nephew | 2 | $39 |
| GSK | 2 | $33 |
| Medtronic | 2 | $33 |
| Merck | 2 | $27 |
| Hill Dermaceuticals, Inc. | 1 | $26 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Amgen | 1 | $18 |
| Heron Therapeutics, Inc. | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Forte Bio-pharma LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Odactra$4,500
- Otiprio$4,500
- Xhance$917
- DUPIXENT$211
- SCOPIS ENT$176
- ENTELLUS - XPRESS ENT DILATION SYSTEM$173
- TEZSPIRE$133
- Relieva Tract$101
How this compares
$11,977 in reported general payments places this provider in the 90th percentile of 180 otolaryngology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azelastine Hcl | 304 | $7,416 |
| Ipratropium Bromide | 153 | $5,948 |
| Fluticasone Propionate | 238 | $4,774 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 39 | $4,483 |
| RyaltrisOlopatadine Hcl/Mometasone | 12 | $4,032 |
| Fluocinolone Acetonide Oil | 51 | $3,201 |
| Omeprazole | 271 | $3,013 |
| Levocetirizine Dihydrochloride | 301 | $2,818 |
| Famotidine | 163 | $2,610 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 14 | $1,755 |
| Cefdinir | 90 | $1,474 |
| Prednisone | 123 | $1,044 |
| Nortriptyline Hcl | 24 | $739 |
| Ofloxacin | 33 | $595 |
| Montelukast Sodium | 51 | $577 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USARyaltris | $16 | $4,03212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 180 otolaryngology providers in South Carolina.
Other otolaryngology in Orangeburg
- Shaun NguyenCharleston$973K
- Rodney SchlosserCharleston$382K
- Zachary SolerCharleston$67K
- Peter HorwichNorth Charleston$33K
- Eugene BrownCharleston$28K
- Jason NewmanCharleston$26K
- Joshua HornigCharleston$25K
- Ashli OrourkeCharleston$21K
- Alexandra KejnerCharleston$19K
- Evan GraboyesCharleston$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.